来自喘患者的循环埃索诺菲尔的单细胞RNA测序揭示了一个炎症特征
Kyndal Goss1,2,3, Melanie L Grant1,2,3, Cherish Caldwell4
1Marcus Center for Advanced Cellular Therapy, Atlanta, GA, USA.
iScience
|June 20, 2025
概括
喘患者的血中乙氨基基酸表现出不同的基因表达模式,包括炎症特征和CCR3表达的增加. 这些发现凸显了对喘中乙氨基基基转录驱动因素进行更大规模研究的需要.
科学领域:
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
- 肺部病理学 肺部病理学
背景情况:
- 喘是美国普遍存在的慢性呼吸道疾病.
- 血中乙氨基酸在喘病原发生过程中起着关键作用.
- 现代的奥米克技术在喘埃索诺菲尔研究中未得到充分利用.
研究的目的:
- 与健康对照组相比,研究患有严重和轻度喘的患者血液中乙酸氨基细胞的基因表达特征.
- 在喘中识别明显的氨基基基子集及其转录特征.
主要方法:
- 单细胞RNA测序 (scRNA-seq) 在血液中氨基酸细胞上进行.
- 从患有严重喘,轻度喘和健康志愿者中分离出埃索诺菲尔.
主要成果:
- 喘患者的乙氨基酸表现出显著的异质性,并被分为3个子集,类似于健康对照.
- 来自喘患者的乙氨基酸显示出炎症基因特征,与干扰素α和γ途径的丰富.
- 喘患者中较高比例的乙氨基细胞表达了CCR3,这是一种对免疫细胞贩运至关重要的受体.
结论:
- 在喘中,血液中异氨基酸在转录上是多样化的,存在着不同的子集.
- 炎症途径和CCR3表达在喘患者的乙酸细胞中被上调.
- 需要进一步的大规模研究来阐明喘的转录驱动因素.
相关概念视频
Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
484
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
484
Asthma: Pathogenesis and Management
618
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
618
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Asthma-I: Introduction
2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Antiasthma Drugs: Leukotriene Modifiers
502
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
502


